Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition. In this Q&A, Christie Ballantyne, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results